Imatinib-Induced Serositis: A Rare Cause of Recurrent Pleural and Pericardial Effusions
Introduction: Imatinib mesylate is first line therapy for chronic phase chronic myeloid leukemia (CML). Serositis is a rare, life-threatening, imatinib-induced complication, reported in 1.3% of newly diagnosed and 2% of other chronic phase CML patients, that may result in respiratory compromise or cardiac tamponade. Case Presentation: 72-year-old-male with CML in molecular remission on imatinib presented with recurrent pleural effusions and new pericardial effusions concerning for pre-tamponade physiology, suspected to be imatinib induced serositis. Imatinib was discontinued with resolution of effusions. The patient was transitioned to nilotinib with maintenance of BCR-ABL negativity and good tolerability. Conclusion: This case highlights the importance of recognizing imatinib-induced serositis. Prompt therapy modification can prevent morbidity while maintaining molecular remission.
Authors
- Ryan P. Zimmerman
- Pallab Sarker
- Fatima Khalid
- Maya Pillai
Institutions
- Reading Hospital (US)
Publication Details
- Journal
- Journal of Community Hospital Internal Medicine Perspectives
- Published
- 2026-11-17
- DOI
- https://doi.org/10.55729/2000-9666.1659
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00